Jain Rita 4

What Happened

• Rita Jain, a director of First Tracks Biotherapeutics, was granted equity awards on 2026-05-12: 15,000 restricted stock units (RSUs) and an award to acquire 42,000 shares (stock options). Both awards are reported as derivative grants at $0.00 per share (no cash paid).
• These are grants (compensation), not open-market purchases or sales. RSUs convert to shares upon settlement; the 42,000-share award is an option grant that would require exercise per its terms (exercise price not provided in the filing excerpt).

Key Details

• Transaction date: 2026-05-12; Filing date: 2026-05-14 (filed timely under Form 4 rules).
• Price/value reported: $0.00 per share (derivative awards); total immediate cash value not shown in the filing.
• Vesting: RSUs vest 100% on the issuer’s 2027 annual meeting of shareholders (footnote F2). The option vests 1/12 of the total shares monthly beginning June 12, 2026 until fully vested (footnote F3).
• Holdings after grant: Reporting person holds the 15,000 RSUs and the newly granted options for 42,000 shares; filing also notes the Reporting Person “also holds additional options to purchase up to an aggregate of 57,135 shares” (footnote F4).
• Transaction code: A = Award/Grant (derivative). No 10b5-1 plan, tax withholding, or late-filing flags noted in the provided data.

Context

• RSUs give a contingent right to receive one share each upon settlement (no purchase required) — they do not represent immediate tradable shares until vested/settled. Options require exercise (and typically payment of an exercise price) before becoming shares; the filing excerpt does not list an exercise price.
• Grants to directors are common compensation and do not by themselves indicate buying or selling intent in the market.